



To: UCM Medical Staff, House staff, Nursing Staff, Patient Care Centers, and Outpatient Clinics

From: Melissa S Pessin, MD, PhD

Professor and Vice Chair, Clinical Pathology

Medical Director of Hyde Park Clinical Laboratories and Alternative Site Testing

Date: 8/11/2025

Subject: Fecal Calprotectin Testing Offered at UCM Clinical Chemistry Lab - Hyde Park

Effective Date: 8/20/2025

Laboratory Section: Chemistry

Summary:

Effective 8/20/2025, the Hyde Park Clinical Chemistry Laboratory will begin performing Fecal Calprotectin testing in-house.

Calprotectin is a calcium-binding protein found in neutrophilic granulocytes, monocytes, and macrophages, comprises up to 60% of the total cytosolic protein content in neutrophils, resists metabolic degradation, and can be measured in feces

Elevated concentrations of fecal calprotectin may be useful in distinguishing IBD from functional gastrointestinal disorders, such as irritable bowel syndrome. When used for this differential diagnosis, fecal calprotectin has sensitivity and specificity both of approximately 85%. However, increases in fecal calprotectin are not diagnostic for IBD, as other disorders such as celiac disease, colorectal cancer, and gastrointestinal infections, may also be associated with neutrophilic inflammation.

Our new test methodology and the reference ranges differ from the reference laboratory test offered by Mayo Clinic Laboratories and thus there will be differences in the quantitative value reported. However, the test characteristics and performance of both tests are comparable.

Test Name: Fecal Calprotectin

Synonym: Stool Calprotectin, Fec Calpro

Test Code: LABCHFCAL CPT Code(s): 83993 Turnaround time: 2-3 days

Testing: Batch testing is performed once per day, Monday through Friday.

Specimen Requirements: Stool without any preservatives 5g, minimum volume 1g.

Results Reporting:

Reference Range	
Interpretation	Fecal Calprotectin
Normal	< 80 mcg/g
Borderline	80 – 160 mcg/g
Elevated	> 160 mcg/g

Questions:

If there are any questions regarding this change, please contact:

- Melissa S Pessin, MD, PhD, Interim Medical Director, Clinical Chemistry Service pessinm@bsd.uchicago.edu
- Clarence Chan, MD, PhD, Assistant Medical Director, Clinical Chemistry Service <u>clarence.chan@bsd.uchicago.edu</u>
- Vishnu Samara, PhD, Assistant Medical Director, Clinical Chemistry Service vsamara@bsd.uchicago.edu